Heterologous SaRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 1

PMID 35911728

Authors

Adrian Rice

Mohit Verma

Emily Voigt

Peter Battisti

Sam Beaver

Sierra Reed

Kyle Dinkins

Shivani Mody

Lise Zakin

Shiho Tanaka

Brett Morimoto

C Anders Olson

Elizabeth Gabitzsch

Jeffrey T Safrit

Patricia Spilman

Corey Casper

Patrick Soon-Shiong

Affiliations

Soon will be listed here.

Abstract

We assessed if immune responses are enhanced in CD-1 mice by heterologous vaccination with two different nucleic acid-based COVID-19 vaccines: a next-generation human adenovirus serotype 5 (hAd5)-vectored dual-antigen spike (S) and nucleocapsid (N) vaccine (AdS+N) and a self-amplifying and -adjuvanted S RNA vaccine (AAHI-SC2) delivered by a nanostructured lipid carrier. The AdS+N vaccine encodes S modified with a fusion motif to increase cell-surface expression and an N antigen modified with an Enhanced T-cell Stimulation Domain (N-ETSD) to direct N to the endosomal/lysosomal compartment and increase MHC class I and II stimulation potential. The S sequence in the AAHI-SC2 vaccine comprises the D614G mutation, two prolines to stabilize S in the prefusion conformation, and 3 glutamines in the furin cleavage region to confer protease resistance. CD-1 mice received vaccination by homologous and heterologous prime > boost combinations. Humoral responses to S were the highest with any regimen that included the AAHI-SC2 vaccine, and IgG bound to wild type and Delta (B.1.617.2) variant S1 at similar levels. An AAHI-SC2 prime followed by an AdS+N boost particularly enhanced CD4+ and CD8+ T-cell responses to both wild type and Delta S peptides relative to all other vaccine regimens. Sera from mice receiving AAHI-SC2 homologous or heterologous vaccination were found to be highly neutralizing for all pseudovirus strains tested: Wuhan, Beta, Delta, and Omicron strains. The findings here, taken in consideration with the availability of both vaccines in thermostable formulations, support the testing of heterologous vaccination by an AAHI-SC2 > AdS+N regimen in animal models of SARS-CoV-2 infection to assess its potential to provide increased protection against emerging SARS-CoV-2 variants particularly in regions of the world where the need for cold-chain storage has limited the distribution of other vaccines.

Citing Articles

Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.

Lykins W, Pollet J, White J, Keegan B, Versteeg L, Strych U Front Immunol. 2024; 15:1480976.

PMID: 39737197 PMC: 11683073. DOI: 10.3389/fimmu.2024.1480976.

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.

Saraf A, Gurjar R, Kaviraj S, Kulkarni A, Kumar D, Kulkarni R Nat Med. 2024; 30(5):1363-1372.

PMID: 38637636 PMC: 11108772. DOI: 10.1038/s41591-024-02955-2.

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19.

Silva-Pilipich N, Beloki U, Salaberry L, Smerdou C Vaccines (Basel). 2024; 12(3).

PMID: 38543952 PMC: 10974399. DOI: 10.3390/vaccines12030318.

Practical Considerations for Next-Generation Adjuvant Development and Translation.

Lykins W, Fox C Pharmaceutics. 2023; 15(7).

PMID: 37514037 PMC: 10385070. DOI: 10.3390/pharmaceutics15071850.

Employing T-Cell Memory to Effectively Target SARS-CoV-2.

Tun Z, Htike N, Kyi-Tha-Thu C, Lee W Pathogens. 2023; 12(2).

PMID: 36839573 PMC: 9967959. DOI: 10.3390/pathogens12020301.

References

Hyseni I, Molesti E, Benincasa L, Piu P, Casa E, Temperton N . Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses. 2020; 12(9). PMC: 7551040. DOI: 10.3390/v12091011. View

Amalfitano A, Hauser M, Hu H, Serra D, Begy C, Chamberlain J . Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 1998; 72(2):926-33. PMC: 124562. DOI: 10.1128/JVI.72.2.926-933.1998. View

Kardani K, Bolhassani A, Shahbazi S . Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine. 2015; 34(4):413-423. DOI: 10.1016/j.vaccine.2015.11.062. View

Tan A, Linster M, Tan C, Bert N, Chia W, Kunasegaran K . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021; 34(6):108728. PMC: 7826084. DOI: 10.1016/j.celrep.2021.108728. View

Rice A, Verma M, Shin A, Zakin L, Sieling P, Tanaka S . Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Sci Rep. 2021; 11(1):14917. PMC: 8295250. DOI: 10.1038/s41598-021-94364-5. View

Wu T, Guarnieri F, Staveley-OCarroll K, Viscidi R, Levitsky H, Hedrick L . Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A. 1995; 92(25):11671-5. PMC: 40464. DOI: 10.1073/pnas.92.25.11671. View

Bangaru S, Ozorowski G, Turner H, Antanasijevic A, Huang D, Wang X . Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020; 370(6520):1089-1094. PMC: 7857404. DOI: 10.1126/science.abe1502. View

Zhu F, Li Y, Guan X, Hou L, Wang W, Li J . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240):1845-1854. PMC: 7255193. DOI: 10.1016/S0140-6736(20)31208-3. View

Tolah A, Sohrab S, Tolah K, Hassan A, El-Kafrawy S, Azhar E . Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay. Diagnostics (Basel). 2021; 11(6). PMC: 8226551. DOI: 10.3390/diagnostics11060994. View

10.

Weissman D, Alameh M, Silva T, Collini P, Hornsby H, Brown R . D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host Microbe. 2020; 29(1):23-31.e4. PMC: 7707640. DOI: 10.1016/j.chom.2020.11.012. View

11.

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L . Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20):1899-1909. PMC: 8091623. DOI: 10.1056/NEJMoa2103055. View

12.

Richardson S, Madzorera V, Spencer H, Manamela N, van der Mescht M, Lambson B . SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022; 30(6):880-886.e4. PMC: 8947963. DOI: 10.1016/j.chom.2022.03.029. View

13.

Zhang C, Maruggi G, Shan H, Li J . Advances in mRNA Vaccines for Infectious Diseases. Front Immunol. 2019; 10:594. PMC: 6446947. DOI: 10.3389/fimmu.2019.00594. View

14.

Tarke A, Sidney J, Kidd C, Dan J, Ramirez S, Yu E . Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021; 2(2):100204. PMC: 7837622. DOI: 10.1016/j.xcrm.2021.100204. View

15.

Lin K, Guarnieri F, Staveley-OCarroll K, Levitsky H, August J, Pardoll D . Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56(1):21-6. View

16.

Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I . Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022; 28(6):1297-1302. DOI: 10.1038/s41591-022-01792-5. View

17.

Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; 27(2):270-278. DOI: 10.1038/s41591-020-01194-5. View

18.

Zhang L, Jackson C, Mou H, Ojha A, Peng H, Quinlan B . SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020; 11(1):6013. PMC: 7693302. DOI: 10.1038/s41467-020-19808-4. View

19.

Sandbrink J, Shattock R . RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. Front Immunol. 2021; 11:608460. PMC: 7783390. DOI: 10.3389/fimmu.2020.608460. View

20.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View